L. Xu

机构：Shanghai Mental Health Center · ORCID：0009-0005-0903-982X

发表论文 12 篇 · 总被引 175 次 · h-index 6

代表论文

• Sedative and hypnotic activities of the ethanol fraction from Fructus Schisandrae in mice and rats (2006 · Journal of Ethnopharmacology · 被引 80)
• High epiregulin ( EREG ) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17—A phase III trial of cetuximab versus best supportive care (BSC) (2009 · Journal of Clinical Oncology · 被引 39)
• K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial (2009 · Journal of Clinical Oncology · 被引 19)
• Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone (2006 · Journal of Clinical Oncology · 被引 17)
• Total polyphenol of A nemarrhena asphodeloides ameliorates advanced glycation end products‐induced endothelial dysfunction by regulation of AMP ‐ K inase (知母多酚通过激活AMP‐激酶来缓解糖基化终末产物引起的内皮损伤) (2013 · Journal of Diabetes · 被引 10)
• 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) (2015 · European Journal of Cancer · 被引 6)